Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 1/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 1/20 | 1.00 |
| ▸ | GABRE | P78334 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicuculline SCHEMBL28213750 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29652597 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29617593 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29390611 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL7913545 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5481014 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5783586 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL8222 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL16320040 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL2532354 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | ANTHEIA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260069680-A1 | HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF | CITY OF HOPE (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260023089-A1 | GENETICALLY ENCODED BIOLUMINESCENT SENSORS | CENTRAL MICHIGAN UNIVERSITY | 2026-01-22 | — | — | US | disclosed |
| US-12502562-B2 | Human iPSC-derived brain organoids and uses thereof | CITY OF HOPE (US) | 2025-12-23 | — | — | US | disclosed |
| US-12497638-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| US-12428656-B2 | Nitrilase mutant and application thereof in the synthesis of 1-cyanocyclohexyl acetic acid | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2025-09-30 | — | — | US | disclosed |
| US-20250288546-A1 | THERAPEUTIC COMPOSITION, METHODS, AND USES FOR THE CONTROL OF SEIZURES | NEUROPRO THERAPEUTICS INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250283873-A1 | NERVOUS SYSTEM CELL-CONTAINING SPHEROID, METHOD FOR PRODUCING NERVOUS SYSTEM CELL-CONTAINING SPHEROID, AND METHOD FOR EVALUATING TEST SUBSTANCE | RICOH COMPANY, LTD. (JP) | 2025-09-11 | — | — | US | disclosed |
| EP-4613846-A1 | NERVOUS SYSTEM CELL-CONTAINING SPHEROID, METHOD FOR PRODUCING NERVOUS SYSTEM CELL-CONTAINING SPHEROID, AND METHOD FOR EVALUATING TEST SUBSTANCE | Ricoh Company, Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4594342-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2022109194-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220162656-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2022-05-26 | — | — | US | disclosed |
| WO-2022098641-A1 | ENHANCED UPTAKE TRANSMUCOSAL DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | PADAGIS ISRAEL PHARMACEUTICALS LTD. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-11325952-B2 | Light-gated signaling modulation | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2022-05-10 | — | — | US | disclosed |
| CN-108463561-B | Methods comprising microrna-based microglia microvesicles for the diagnosis, prognosis and therapeutic monitoring of neurological, neurodegenerative and inflammatory based diseases | 布兰迪技术责任有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114302951-A | Methods for increasing production of morphinan alkaloids and derivatives | 安思雅公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114222818-A | cPLA2e inducer and use thereof | 基础应用医学研究基金会 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022040432-A1 | ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF RETT SYNDROME | STRIDEBIO, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3947633-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-107002103-B | Nostocarin-like producing microorganisms and methods of making and using the same | 小利兰.斯坦福大学托管委员会 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288546-A1 | THERAPEUTIC COMPOSITION, METHODS, AND USES FOR THE CONTROL OF SEIZURES | GAP43, GABRB3, GABRB2 | CYP3A4 4249/4885CYP2C9 4309/4885CYP2C19 3918/4885 |
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | OPRK1, OPRM1, OPRD1 | CYP3A4 13/4885CYP2C9 27/4885CYP2C19 40/4885 |
| US-20260069680-A1 | HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF | PDGFRA, PDGFRB, PDGFA | CYP3A4 3174/4885CYP2C9 4237/4885CYP2C19 3132/4885 |
| US-20260023089-A1 | GENETICALLY ENCODED BIOLUMINESCENT SENSORS | SLC18A2, SLC18A3, SLC6A13 | CYP3A4 3824/4885CYP2C9 4220/4885CYP2C19 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.